A subscription to JoVE is required to view this content. Sign in or start your free trial.

Method Article

Production, Crystallization, and Structure Determination of the IKK-binding Domain of NEMO

6.6K views

⸱

DOI:

10.3791/60339

⸱

December 28th, 2019

 ,  ,  , 

In This Article

Summary

We describe protocols for the structure determination of the IKK-binding domain of NEMO by X-ray crystallography. The methods include protein expression, purification and characterization as well as strategies for successful crystal optimization and structure determination of the protein in its unbound form.

Abstract

NEMO is a scaffolding protein which plays an essential role in the NF-κB pathway by assembling the IKK-complex with the kinases IKKα and IKKβ. Upon activation, the IKK complex phosphorylates the IκB molecules leading to NF-κB nuclear translocation and activation of target genes. Inhibition of the NEMO/IKK interaction is an attractive therapeutic paradigm for the modulation of NF-κB pathway activity, making NEMO a target for inhibitors design and discovery. To facilitate the process of discovery and optimization of NEMO inhibitors, we engineered an improved construct of the IKK-binding domain of NEMO that would allow for structure determination of the protein in the apo form and while bound to small molecular weight inhibitors. Here, we present the strategy utilized for the design, expression and structural characterization of the IKK-binding domain of NEMO. The protein is expressed in E. coli cells, solubilized under denaturing conditions and purified through three chromatographic steps. We discuss the protocols for obtaining crystals for structure determination and describe data acquisition and analysis strategies. The protocols will find wide applicability to the structure determination of complexes of NEMO and small molecule inhibitors.

Introduction

The NF-κB pathway is activated in response to a variety of stimuli, including cytokines, microbial products and stress, to regulate expression of target genes responsible for inflammatory and immune response, cell death or survival and proliferation1. Pathologies including inflammatory and autoimmune diseases and cancer2,3,4,5 have been correlated to hyperactivation of the pathway, which has made modulation of NF-κB activity a prime target for the development of new therapies6,

Access restricted. Please log in or start a trial to view this content.

Protocol

1. Design of construct for crystallography

  1. Clone the sequence of NEMO-EEAA as in previous publication12 in a vector for expression in E. coli using the T7 promoter, including a N-terminal hexa-histidine tag and a protease cleavage site.
    NOTE: In this protocol, we used a vector modified to include a N-terminal hexa-histidine tag and a Tobacco Etch Virus (TEV) cleavage site10. This vector facilitates cleavage of the His tag for protein crystallization and leaves only the short extension of GSW residues before the start of the desired protein sequence. The vector from which this was derived, and ....

Access restricted. Please log in or start a trial to view this content.

Results

Cloning, expression and purification of the IKK-binding domain of NEMO.
The protocol followed in this study to obtain the final sequence of NEMO-EEAA (Figure 1A), which produced diffraction quality crystals, involved the expression and characterization of all the intermediate constructs, including the addition of the coiled-coil adaptors at N- and or C-terminus, the mutations C76A, C95S and the mutations E56A, E57A. Figure 1.......

Access restricted. Please log in or start a trial to view this content.

Discussion

Crystallization attempts of NEMO in the unbound form were unsuccessful, including attempts using the full-length protein and several truncation constructs encompassing the IKK-binding domain. Our biophysical characterization of the IKK-binding domain of NEMO (residues 44-111) by circular dichroism, NMR spectroscopy and fluorescence anisotropy indicated that the construct, albeit able to bind IKKβ, existed in a state of conformational exchange, not suitable for crystallization9,

Access restricted. Please log in or start a trial to view this content.

Disclosures

The authors declare no competing interests.

Acknowledgements

We thank Prof. D. Madden, for many helpful discussions throughout this project. We thank Prof. D. Bolon for the gift of the plasmid containing the optimized GCN4 coiled coil. We thank Dr. B. Guo for NEMO plasmids. We thank Christina R. Arnoldy, Tamar Basiashvili and Amy E. Kennedy for demonstrating the procedure. We thank the BioMT Crystallography Core Facility and the departments of Chemistry and of Biochemistry & Cell Biology at Dartmouth for the use of the crystallography equipment and the BioMT personnel for their support. This research used the AMX beamline of the National Synchrotron Light Source II, a U.S. Department of Energy (DOE) Office of Science User F....

Access restricted. Please log in or start a trial to view this content.

Materials

List of materials used in this article
NameCompanyCatalog NumberComments
20% w/v γ-PGA (Na+ form, LM)Molecular DimensionsMD2-100-150For fine screen crystallization of NEMO-EEAA
3.5 kDa MWCO Dialysis MembraneSpectra/Por132724For dialysis removal of imidazole
Amicon Stirred CellMillipose SigmaUFSC 05001For protein concentration
Ammonium ChlorideMillipore SigmaG8270For minimal media labeling
Benzonase NucleaseMillipore Sigma9025-65-4For digestion of nucleic acid
BL21-CodonPlus (DE3)-RIL Competent CellsAgilent TechnologiesModel: 230245TEV expression
CryoProHampton ResearchHR2-073Cryo-protectants kit
D-Glucose (Dextrose)Millipore SigmaA9434For minimal media labeling
Difco Terrific BrothThermoFisherDF043817For culture growth
Dithiothreitol > 99%GoldbioDTT25For reduction of disulfides
E. coli: Rosetta 2 (DE3)Novagen71400-3Expression of unlabeled NEMO-EEAA
FORMULATORFormulatrixLiquid handler/ screen builder
HCl – 1.0 M SolutionHampton ResearchHR2-581For fine screen crystallization of NEMO-EEAA
HiLoad 16/600 Superdex 75 pgGE Healthcare28989333For size exclusion purification
HisTrap HP 5 mL columnGE Healthcare17524802For purification of His-tagged NEMO-EEAA
HT 96 MIDASMolecular DimensionsMD1-59For sparse matrix screening of NEMO-EEAA
HT 96 MorpheousMolecular DimensionsMD1-46For sparse matrix screening of NEMO-EEAA
ImidazoleThermoFisher288-32-4For elution from His-trap column
Isopropyl-beta-D-thiogalactosideGoldbioI2481C5For induction of cultures
MRC2 crystallization plateHampton ResearchHR3-083Crystallization plate
NT8 - Drop SetterFormulatrixCrystallization
pET-16bMillipore Sigma69662For cloning of NEMO-EEAA
pET-45bMillipore Sigma71327For cloning of NEMO-EEAA
Phenylmethylsulfonyl fluorideThermoFisher36978For inhibition of proteases
Polycarbonate Bottle for use in Ultracentrifuge Rotor Type 45 TiBeckmann Coulter339160Ultracentrifuge bottle
Polyethylene Glycol 20,000Hampton ResearchHR2-609For fine screen crystallization of NEMO-EEAA
pRK793 (TEV)AddgenePlasmid 8827For TEV production
QuikChange XL IIAgilent Technologies200522Site directed mutagenesis
Required Cap Assembly:Beckmann Coulter355623Ultracenttrifuge bottle cap
ROCK IMAGERFormulatrixCrystallization Imager
Seed Bead KitHampton ResearchHR2-320Seed generation
Sodium Chloride ≥ 99%Millipore SigmaS9888For buffering of purification solutions
TCEP (Tris (2-Carboxyethyl) phosphine Hydrochloride)GoldbioTCEP1Reducing agent
The Berkeley ScreenRigakuMD15-BerekelyFor sparse matrix screening of NEMO-EEAA
The PGA ScreenMolecular DimensionsMD1-50For fine screen crystallization of NEMO-EEAA
Tris – 1.0 M SolutionHampton ResearchHR2-589For fine screen crystallization of NEMO-EEAA
Ultrapure Tris Buffer (powder format)Thermofisher15504020For buffering of purification solutions
UreaThermoFisher29700For denaturation of NEMO-EEAA

References

  1. Gilmore, T. D. Introduction to NF-kappaB: players, pathways, perspectives. Oncogene. 25 (51), 6680-6684 (2006).
  2. Bassères, D. S., Baldwin, A. S. Nuclear factor-kappaB and inhibitor of kappaB kinase pathways in oncogenic initiation and progression. Oncog....

Access restricted. Please log in or start a trial to view this content.

Reprints and Permissions

Explore More Articles

NEMO ProteinProtein ExpressionChromatographic PurificationSize ExclusionCrystallization ScreeningX-ray DiffractionMolecular ReplacementCoiled-coil AdapterTEV Protease